Binge-eating disorder (BED) is a serious eating disorder characterized by recurrent episodes of excessive food consumption accompanied by a sense of loss of control. According to Nader Salari et al., 2025, a systematic review and meta-analysis reported that the global prevalence of eating disorders in children and adolescents was 22.3% during 1999-2022. Current therapies for BED include cognitive-behavioral therapy, pharmacological treatments, and lifestyle interventions. The growing focus on innovative drug development and personalized treatments is driving the pipeline. According to the binge-eating disorder pipeline analysis by Expert Market Research, the treatment landscape is expected to expand in the coming years.
Major companies involved in the binge-eating disorder pipeline analysis include Axsome Therapeutics, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc., and others.
Leading drugs currently in the pipeline include Solriamfetol, TNX-1900, and others.
The binge-eating disorder drug pipeline is expanding, driven by novel pharmacological therapies targeting appetite regulation, increased clinical trial activity, and rising investment in innovative treatments to address unmet patient needs.
The Binge-Eating Disorder Pipeline Analysis Report by Expert Market Research gives comprehensive insights into binge-eating disorder therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for binge-eating disorder. The binge-eating disorder report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The binge-eating disorder pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with binge-eating disorder treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to binge-eating disorder.
Read more about this report - Request a Free Sample
Binge-eating disorder is a serious eating condition characterized by recurrent episodes of consuming unusually large amounts of food with a feeling of loss of control. It often occurs due to emotional stress, psychological factors, or neurobiological imbalances, leading to overeating even when not physically hungry. The disorder can result in weight gain, social isolation, and associated health complications.
Binge-eating disorder treatments include pharmacological interventions such as lisdexamfetamine dimesylate, cognitive-behavioral therapy, and lifestyle modifications, focusing on controlling compulsive eating, improving emotional regulation, and reducing health risks. In the binge-eating disorder market, Vyvanse (lisdexamfetamine dimesylate) represents a key pipeline drug, approved by the FDA in August 2023. Its generic formulations offer effective management of moderate to severe BED, providing clinicians with additional therapeutic options.
According to recent epidemiological studies, the prevalence of binge-eating disorder has been rising globally. Between 2000 and 2018, its occurrence more than doubled, reaching 7.8% of the general population. A 2023 meta-analysis further reported that eating disorders among children and adolescents affected 22.3% worldwide from 1999 to 2022. These trends highlight the growing need for novel therapeutic interventions in the drug development pipeline.
This section of the report covers the analysis of binge-eating disorder drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The binge-eating disorder pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II (with 46%) covers a major share of the total binge-eating disorder clinical trials. It is followed by phase I at 23% and early phase I at 15%. The strong presence in phase II and I indicate robust clinical activity, which can positively drive innovation, future approvals, and market growth in the binge-eating disorder segment.
The drug molecule categories covered under the binge-eating disorder pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and proteins. The binge-eating disorder report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for binge-eating disorder. Stimulant-based drug therapies are also being explored as effective interventions for binge-eating disorder. For instance, lisdexamfetamine, the only FDA-approved pharmacological treatment for moderate-to-severe binge-eating disorder, showed significant benefits in clinical trials. When combined with cognitive behavioral therapy, it resulted in a 96% reduction in binge-eating episodes, a 70% remission rate, and meaningful weight loss in patients with obesity.
The EMR report for the binge-eating disorder pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed binge-eating disorder therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in binge-eating disorder clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for binge-eating disorder. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of binge-eating disorder drug candidates.
Solriamfetol, developed by Axsome Therapeutics, Inc., is a dopamine and norepinephrine reuptake inhibitor and TAAR1 agonist currently being evaluated in a Phase 3, open-label study for adults with binge-eating disorder (BED). This study is examining the long-term safety and efficacy of solriamfetol at 75 mg, 150 mg, and 300 mg doses. It includes a titration and 50-week maintenance phase to assess its impact on reducing binge-eating episodes while monitoring tolerability.
TNX-1900 is an intranasal potentiated oxytocin being developed by Tonix Pharmaceuticals for the treatment of binge-eating disorder. Sponsored by Massachusetts General Hospital, this Phase 2 study is evaluating the effects of TNX-1900 versus placebo over eight weeks in adults with binge-eating episodes. The study is examining reductions in binge frequency, safety, and tolerability while exploring changes in appetite regulation, reward sensitivity, and impulse control. TNX-1900 delivers oxytocin directly to the trigeminal system, enhancing receptor binding and targeting neural pathways linked to binge behavior.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Binge-Eating Disorder Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for binge-eating disorder. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into binge-eating disorder collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share